SCHEMBL2040802

SCHEMBL2040802

COc1cc(CN)ccc1N

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.74
CYP3A4 P08684 3/20 0.57
TSHR P16473 3/20 0.57
TDP1 Q9NUW8 2/20 0.57
HSD17B10 Q99714 1/20 0.57
GAA P10253 1/20 0.52
KDM4E B2RXH2 1/20 0.50
ATM Q13315 1/20 0.50
CYP19A1 P11511 2/20 0.47
TAAR1 Q96RJ0 2/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
CA2 P00918 1/20 0.47
APP P05067 2/20 0.46
LMNA P02545 1/20 0.46
GLA P06280 1/20 0.46
ADRA2B P18089 1/20 0.45
PTGS1 P23219 1/20 0.45
LOX P28300 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30541678 0.85 ALDH1A1 (1.00) ALDH1A1CYP3A4TSHRTDP1HSD17B10
SCHEMBL9516946 0.85 ALDH1A1 (0.77) ALDH1A1CYP3A4TSHRTDP1HSD17B10
SCHEMBL273470 0.85 ALDH1A1 (1.00) ALDH1A1CYP3A4TSHRTDP1HSD17B10
SCHEMBL2019108 0.84 KDM4E (0.72) ALDH1A1CYP3A4TSHRTDP1HSD17B10
SCHEMBL5831938 0.83 ALDH1A1 (0.74) ALDH1A1CYP3A4TSHRTDP1HSD17B10
SCHEMBL1725006 0.83 GAA (0.74) ALDH1A1CYP3A4TSHRTDP1GAA
SCHEMBL29535675 0.83 ATM (0.70) ALDH1A1CYP3A4TSHRGAAKDM4E
SCHEMBL44393 0.83 ATM (0.70) ALDH1A1CYP3A4TSHRGAAKDM4E
SCHEMBL19409880 0.83 ATM (0.70) ALDH1A1CYP3A4TSHRGAAKDM4E
SCHEMBL2033379 0.82 ALDH1A1 (0.71) ALDH1A1CYP3A4TSHRTDP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240229089-A1 A process for enzymatic synthesis of amides from amines and carboxylic acids or esters XP CHEMISTRIES AB (SE) 2024-07-11 US disclosed
US-20240229089-A1 A process for enzymatic synthesis of amides from amines and carboxylic acids or esters XP CHEMISTRIES AB (SE) 2024-07-11 US disclosed
WO-2022218379-A1 SMALL-MOLECULE COMPOUND HAVING SUBSTITUTED PHENYL SPIRO[INDOLINE-3,3'-PYRROLIDINE] STRUCTURE 中国科学院上海药物研究所 2022-10-20 WO disclosed
EP-2516387-B1 INHIBITORS OF CYCLOPHILINS FOR USE IN THE PREVENTION AND/OR THE TREATMENT OF VIRAL PATHOLOGIES OR INFECTIONS INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE (INSERM) (FR) 2018-02-21 EP disclosed
EP-2137179-B1 PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS MERCK SHARP & DOHME (US) 2015-09-02 EP disclosed
CN-102971291-B Novel amide derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORP 2015-07-22 CN disclosed
WO-2014202787-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST L'OREAL (FR) 2014-12-24 WO disclosed
US-8901295-B2 Inhibitors of cyclophilins and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-12-02 US disclosed
US-8802666-B2 Inhibitors of cyclophilins and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-08-12 US disclosed
US-20140179687-A1 New Inhibitors of Cyclophilins and Uses Thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-06-26 US disclosed
US-20130018044-A1 NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2013-01-17 US disclosed
EP-2516387-A2 NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2012-10-31 EP disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
WO-2011076784-A2 NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2011-06-30 WO disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
WO-2008115381-A1 PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2008-09-25 WO disclosed
US-4217272-A DYEING CELLULOSIC FIBERS STERLING DRUG INC. (US) 1980-08-12 US disclosed
US-4153598-A Monoazo and diazo colorants from aminoalkylanilines and bis(aminoalkyl)anilines STERLING DRUG INC. (US) 1979-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA ALDH1A1 2437/4885CYP3A4 281/4885TSHR 4729/4885
US-20140179687-A1 New Inhibitors of Cyclophilins and Uses Thereof FKBP3, FKBP4, FKBP5 ALDH1A1 3684/4885CYP3A4 295/4885TSHR 1189/4885
US-20130018044-A1 NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF FKBP3, FKBP4, FKBP5 ALDH1A1 3684/4885CYP3A4 295/4885TSHR 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.